GlaxoSmithKline highlights positive data for diabetes drug

GlaxoSmithKline has highlighted positive data from phase III clinical studies of albiglutide, its new therapy for type 2 diabetes.

Top-line results have now been received from seven out of the eight trials in the phase III Harmony programme, with data from Harmony 6 showing clinically significant reductions in glycated haemoglobin levels and non-inferiority versus preprandial lispro insulin.

Results from Harmony 7 has already been announced in November 2011, while positive findings have also been extracted from the Harmony 1 to 5 studies, though full details remain confidential while the trials are ongoing.

Harmony 8 is also yet to be completed, with results from this study expected in mid-2012.

GlaxoSmithKline believes that the data gathered from the trials so far supports progression towards regulatory submissions for albiglutide as a possible once-weekly treatment for type 2 diabetes.

This comes after the firm also confirmed plans to push ahead with regulatory filings for its respiratory disease therapy Relovair last month.